Sign In
Buy 0HC7
Albemarle Earnings Calls
| Release date | Nov 05, 2025 |
| EPS estimate | -$0.86 |
| EPS actual | -$0.190 |
| EPS Surprise | 77.94% |
| Revenue estimate | 1.321B |
| Revenue actual | 1.308B |
| Revenue Surprise | -0.99% |
| Release date | Jul 30, 2025 |
| EPS estimate | -$0.84 |
| EPS actual | $0.195 |
| EPS Surprise | 123.24% |
| Revenue estimate | 1.271B |
| Revenue actual | 1.33B |
| Revenue Surprise | 4.64% |
| Release date | Apr 30, 2025 |
| EPS estimate | -$0.661 |
| EPS actual | -$0.180 |
| EPS Surprise | 72.75% |
| Revenue estimate | 1.164B |
| Revenue actual | 1.077B |
| Revenue Surprise | -7.52% |
| Release date | Feb 12, 2025 |
| EPS estimate | -$0.690 |
| EPS actual | $0.640 |
| EPS Surprise | 192.76% |
| Revenue estimate | 1.336B |
| Revenue actual | 1.232B |
| Revenue Surprise | -7.79% |
Last 4 Quarters for Albemarle
Below you can see how 0HC7.L performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 12, 2025 |
| Price on release | $75.88 |
| EPS estimate | -$0.690 |
| EPS actual | $0.640 |
| EPS surprise | 192.76% |
| Date | Price |
|---|---|
| Feb 06, 2025 | $79.27 |
| Feb 07, 2025 | $77.16 |
| Feb 10, 2025 | $76.48 |
| Feb 11, 2025 | $74.88 |
| Feb 12, 2025 | $75.88 |
| Feb 13, 2025 | $79.27 |
| Feb 14, 2025 | $80.77 |
| Feb 17, 2025 | $80.77 |
| Feb 18, 2025 | $80.08 |
| 4 days before | -4.28% |
| 4 days after | 5.54% |
| On release day | 4.46% |
| Change in period | 1.02% |
| Release date | Apr 30, 2025 |
| Price on release | $58.12 |
| EPS estimate | -$0.661 |
| EPS actual | -$0.180 |
| EPS surprise | 72.75% |
| Date | Price |
|---|---|
| Apr 24, 2025 | $57.94 |
| Apr 25, 2025 | $57.42 |
| Apr 28, 2025 | $59.06 |
| Apr 29, 2025 | $59.63 |
| Apr 30, 2025 | $58.12 |
| May 01, 2025 | $59.12 |
| May 02, 2025 | $60.92 |
| May 05, 2025 | $58.01 |
| May 06, 2025 | $57.24 |
| 4 days before | 0.311% |
| 4 days after | -1.51% |
| On release day | 1.72% |
| Change in period | -1.20% |
| Release date | Jul 30, 2025 |
| Price on release | $70.66 |
| EPS estimate | -$0.84 |
| EPS actual | $0.195 |
| EPS surprise | 123.24% |
| Date | Price |
|---|---|
| Jul 24, 2025 | $85.74 |
| Jul 25, 2025 | $83.04 |
| Jul 28, 2025 | $78.06 |
| Jul 29, 2025 | $71.54 |
| Jul 30, 2025 | $70.66 |
| Jul 31, 2025 | $68.30 |
| Aug 01, 2025 | $66.06 |
| Aug 04, 2025 | $68.11 |
| Aug 05, 2025 | $68.13 |
| 4 days before | -17.59% |
| 4 days after | -3.58% |
| On release day | -3.34% |
| Change in period | -20.54% |
| Release date | Nov 05, 2025 |
| Price on release | $92.01 |
| EPS estimate | -$0.86 |
| EPS actual | -$0.190 |
| EPS surprise | 77.94% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $100.12 |
| Oct 31, 2025 | $98.87 |
| Nov 03, 2025 | $98.05 |
| Nov 04, 2025 | $89.84 |
| Nov 05, 2025 | $92.01 |
| Nov 06, 2025 | $91.26 |
| Nov 07, 2025 | $97.83 |
| Nov 10, 2025 | $102.02 |
| Nov 11, 2025 | $103.18 |
| 4 days before | -8.10% |
| 4 days after | 12.14% |
| On release day | -0.82% |
| Change in period | 3.06% |
Albemarle Earnings Call Transcript Summary of Q3 2025
Albemarle reported Q3 2025 net sales of $1.3 billion and adjusted EBITDA of $226 million (up 7% year-over-year) driven by cost and productivity improvements that more than offset lower lithium pricing. Operating cash flow was $356 million (a 57% YoY increase), and management now expects full‑year 2025 positive free cash flow of $300–$400 million. Lithium demand remains strong (consumption up >30% YTD) with grid/storage up ~105% YTD; lithium pricing is being modeled around ~$9–$9.50/kg for the year and the company expects results near the upper end of its $9/kg scenario. Albemarle achieved about $450 million run‑rate cost and productivity improvements and reduced 2025 CapEx to roughly $600 million (a ~65% reduction YoY). The company announced two transactions related to Ketjen (sale of a 51% stake in refining catalysts and sale of Eurecat JV interest) expected to generate ~ $660 million gross proceeds in H1 2026, improving financial flexibility to delever the balance sheet. Operational highlights include record integrated lithium conversion production, lower inventories, and about 45% of 2025 lithium salt volumes expected to be sold on long‑term agreements with floors (mix impacted by China spot sales). Management emphasized continued focus on cost discipline, cash conversion, maintaining optionality for future investments, and readiness to pivot if market economics improve.
